| Gilead Sciences14 programs in shared conditions | 6 · 4 with both in phase 3HIV Infections, Liver Cirrhosis, Biliary, Multiple Myeloma +3 | lenacapavir, teropavimab, zinlirvimab +6 | - Gilead Sciences’ lenacapavir in a combination vs cabotegravir (US & EU rights: GlaxoSmithKline) (HIV Infections, NCT07682961)
- Gilead Sciences’ teropavimab in a combination vs cabotegravir (US & EU rights: GlaxoSmithKline) (HIV Infections, NCT07682961)
- Gilead Sciences’ zinlirvimab in a combination vs cabotegravir (US & EU rights: GlaxoSmithKline) (HIV Infections, NCT07682961)
- and 6 more
|
| Pfizer10 programs in shared conditions | 11 · 7 with both in phase 3Asthma, Endometrial Neoplasms, Multiple Myeloma +8 | tilrekimig, etrasimod, tucatinib +4 | - GlaxoSmithKline’s Pn-MAPS30plus in a combination vs Pneumococcal 20-Valent Conjugate Vaccine (most trials: Pfizer) (Pneumonia, Bacterial, NCT07428759)
- GlaxoSmithKline’s Pn-MAPS30plus in a combination vs Pneumococcal 20-Valent Conjugate Vaccine (most trials: Pfizer) (Pneumonia, Bacterial, NCT07406334)
- GlaxoSmithKline’s Pn-MAPS30plus in a combination vs Pneumococcal 20-Valent Conjugate Vaccine (most trials: Pfizer) (Pneumonia, Bacterial, NCT07406347)
- and 1 more
|
| Johnson & Johnson15 programs in shared conditions | 6 · 2 with both in phase 3Multiple Myeloma, Prostatic Neoplasms, Colitis, Ulcerative +3 | guselkumab, JNJ-78934804, icotrokinra +5 | - GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT04246047)
- GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06868654)
- GlaxoSmithKline’s belantamab mafodotin in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06868667)
- and 1 more
|
| Merck & Co., Inc17 programs in shared conditions | 11 · 8 with both in phase 3Endometrial Neoplasms, HIV Infections, Influenza, Human +8 | tulisokibart, sacituzumab tirumotecan, islatravir +5 | - GlaxoSmithKline’s mocertatug rezetecan vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Ovarian Neoplasms, NCT07286266)
- GlaxoSmithKline’s mocertatug rezetecan added to pembrolizumab (US & EU rights: Merck & Co., Inc) (Endometrial Neoplasms, NCT07684599)
- GlaxoSmithKline’s MMRVNS vaccine in a combination vs measles, mumps, rubella, varicella vaccine (most trials: Merck & Co., Inc) (Measles, NCT07742644)
|
| Guangzhou Patronus Biotech Co., Ltd.5 programs in shared conditions | 3Herpes Zoster, Malaria, Respiratory Syncytial Virus Infections | — | - Guangzhou Patronus Biotech Co., Ltd.’s LYB004 vs shingrix (most trials: GlaxoSmithKline) (Herpes Zoster, NCT06874842)
- Guangzhou Patronus Biotech Co., Ltd.’s LYB004 in a combination vs shingrix (most trials: GlaxoSmithKline) (Herpes Zoster, NCT06335849)
|